Welcome to our dedicated page for Bio Green Med Solution SEC filings (Ticker: BGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Bio Green Med Solution, Inc. (BGMS) brings together the company’s official reports to the U.S. Securities and Exchange Commission, including Form 8-K current reports and other key documents. These filings describe how the company has transitioned from its former identity as Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, to a diversified business focused primarily on fire safety protection and distribution activities anchored by its acquisition of FITTERS Sdn. Bhd. in Malaysia.
Through its 8-K filings, Bio Green Med Solution, Inc. discloses material events such as the completion of the FITTERS Sdn. Bhd. share exchange transaction, the Asset Purchase Agreement with Tethra Biosciences Inc. for the sale of patent rights related to plogosertib, and the liquidation of its UK subsidiary, Cyclacel Limited. These documents also cover capital markets actions, including a one-for-fifteen reverse stock split of its common stock, Warrant Exchange Agreements that exchanged existing warrants for new common shares, and a Nasdaq notice regarding the minimum Market Value of Publicly Held Shares requirement for its 6% Convertible Exchangeable Preferred Stock (BGMSP).
Filings further address governance and compensation matters, such as the resignation and appointment of independent directors, committee assignments for the Audit, Compensation and Organization, and Nominating and Governance Committees, and confirmation of director independence and financial literacy under SEC and Nasdaq standards. Dividend declarations on the company’s 6% Convertible Exchangeable Preferred Stock are also documented in Form 8-K reports.
On this page, users can access Bio Green Med Solution, Inc.’s SEC filings as they are made available from EDGAR and review AI-generated summaries that explain the main points of lengthy documents, including 10-K annual reports, 10-Q quarterly reports, and Form 4 insider transaction reports where applicable. These tools help readers quickly understand complex regulatory disclosures, track changes in the company’s business focus, and follow developments affecting its common and preferred equity securities.
Cyclacel Pharmaceuticals, Inc. (now Bio Green Med Solution, Inc.) filed an amended Annual Report mainly to replace its prior audits with a single firm’s re-audit of full-year
The business is now focused on a single clinical asset, plogosertib ("plogo"), a PLK1 inhibitor in a Phase 1/2 trial for solid tumors and lymphomas, while the fadraciclib program is being sold out of the liquidated U.K. subsidiary. A
The report highlights substantial doubt about the company’s ability to continue as a going concern, dependence on additional capital, significant clinical, regulatory and competitive risks, and potential Nasdaq listing and dilution pressures. As of
Bio Green Med Solution, Inc. (BGMS) reported an insider transaction on Form 4. Director and Chief Financial Officer Kiu Cu Seng acquired 200,000 shares of common stock at $1.40 per share on 11/12/2025.
Following the transaction, the reporting person beneficially owned 200,000 shares, held in direct ownership. The filing was made by one reporting person.
Bio Green Med Solution (BGMS) reported an insider transaction on a Form 4: its Chief Executive Officer, who is also a Director and 10% Owner, acquired 300,178 shares of common stock at $1.4 on 11/12/2025.
Following this trade, the reporting person beneficially owns 1,111,131 shares, held directly. The filing notes share figures are adjusted for a 1-for-16 reverse stock split on May 12, 2025 and a 1-for-15 reverse stock split on July 7, 2025.
Bio Green Med Solution, Inc. (BGMS) reported third-quarter results and detailed its transition from biopharma to fire safety distribution following the September 12, 2025 acquisition of Malaysia-based Fitters Sdn. Bhd. BGMS recognized $81,000 in Q3 revenue, all from fire safety products, and posted a Q3 operating loss of $992,000 with a $988,000 net loss. For the nine months, revenue was $81,000 and net loss was $2.387 million.
Cash and cash equivalents were $3.838 million and total assets $8.158 million as of September 30, 2025. Stockholders’ equity improved to $7.096 million from a deficit at year-end 2024, aided by a $4.947 million gain on deconsolidation after its UK subsidiary entered liquidation. BGMS issued 699,158 shares (19.99%) as consideration for Fitters, recording $1.570 million of goodwill. The company also completed reverse stock splits (1-for-16 in May and 1-for-15 in July) and reported 3,497,537 common shares outstanding at quarter-end; 4,900,142 were outstanding as of November 11, 2025.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, noting current cash is expected to fund operations into the first quarter of 2026. Subsequent to quarter-end, BGMS agreed to sell Plogosertib-related assets for $300,000 plus a potential $170,000 milestone.
Bio Green Med Solution, Inc. furnished a Form 8-K announcing it issued a press release with its third quarter 2025 results. The disclosure was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
The press release is attached as Exhibit 99.1 and dated November 13, 2025. The company’s securities are listed on the Nasdaq Capital Market under BGMS (common) and BGMSP (preferred).
Bio Green Med Solution, Inc. entered into a Warrant Exchange Agreement on November 5, 2025 with certain accredited investors. The Company agreed to exchange previously issued warrants for an aggregate of 1,402,605 shares of common stock, replacing those warrants on a one-for-one basis.
The exchanged warrants were originally issued under a securities purchase agreement dated June 20, 2025. The new shares will be issued without registration in reliance on Section 3(a)(9) of the Securities Act. This exchange is a non-cash transaction that converts contingent warrant rights into issued common shares.
Bio Green Med Solution (BGMS) reported an insider transaction by Yap Kim Choy, a director and 10% owner, on 11/05/2025. The filing shows a sale of 28,540 shares of common stock at a price of $1.70 per share. Separately, the reporting person acquired 467,535 shares of common stock at $0 pursuant to a warrant exchange agreement dated November 5, 2025. Following these transactions, the reporting person directly owned 467,535 common shares.
The exchange retired warrants covering the same number of underlying shares: 218,000 Series A (exercise price $7.65), 218,000 Series B ($9.00), and 31,535 Series C ($10.20), each originally exercisable from 06/20/2025 to 06/20/2030.
Bio Green Med Solution (BGMS) insider filed a Form 4 reporting a warrant-for-share exchange. On November 5, 2025, the reporting person acquired 467,535 shares of Common Stock (transaction code J) at $0 per share under a warrant exchange agreement.
The exchange covered 218,000 Series A warrants at $7.65, 218,000 Series B warrants at $9, and 31,535 Series C warrants at $10.2, each originally exercisable from 06/20/2025 and expiring on 06/20/2030. Following the transaction, the reporting person held 467,535 Common Stock directly and 0 derivative securities.
Bio Green Med Solution (BGMS): A 10% owner, Ong Yee Lung, exchanged outstanding warrants for common stock. On November 5, 2025, the holder acquired 467,535 shares of common stock at $0 in a warrant exchange agreement, reported as a direct holding.
The exchange covered 218,000 Series A warrants (exercise price $7.65), 218,000 Series B warrants ($9), and 31,535 Series C warrants ($10.20), each originally exercisable from June 20, 2025 to June 20, 2030. Following the transaction, the reporting person held 467,535 common shares and 0 derivative securities.
Bio Green Med Solution, Inc. (BGMS) reported an insider transaction. On 10/30/2025, Yap Kim Choy filed a Form 4 showing a sale of 112,260 shares of common stock at $1.807 per share (transaction code S). Following the sale, the reporting person directly owned 28,500 shares. The filing indicates direct ownership for the remaining holdings.
FAQ
What is the current stock price of Bio Green Med Solution (BGMS)?
What is the market cap of Bio Green Med Solution (BGMS)?
